Replies to post #91406 on Biotech Values

[genisi]

From MRK’s 10-K on the pipeline pruning:

Merck has discontinued internal development of MK-2866 (which is a SARM) under this agreement, and is currently discussing next steps with GTx.

Page 128, 2nd paragraph

http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzcxMDk4fENoaWxkSUQ9MzY4MDQ2fFR5cGU9MQ==&t=1